AMRX Stock Analysis: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$16.66
0.55 (3.41%)
▲
5d:
+2.59%
30d:
+34.14%
90d:
+39.77%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRX trades at premium valuation expecting 5.7% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: AMRX trades at premium valuation expecting 5.7% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.62
Based on 8.9% avg growth
INTRINSIC VALUE TODAY
$13.43
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $16.66, which is considered extended relative to its 30-day fair value range of $12.30 to $15.71. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.8) compared to its historical average (12.6). At these levels, the market is pricing in 5.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $16.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: AMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $16.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: AMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.30 -
$15.71
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
AMRX is technically overbought (RSI 79). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+6.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- NEUTRAL: Near Wall St target ($17.25)
- NEUTRAL: PE elevated vs history but 5.7% growth expectation is conservative given 385% recent growth
Trading Range Analysis
30-Day Trading Range
$12.30 -
$15.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.79
Resistance Level
$16.73
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.83
Wall Street Target
$17.25
(+3.5%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
384.6%
Profit Margin
4.0%
Valuation Premium vs History
+5.7% premium
PE vs Historical
14.8 vs 12.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.7%
(market-implied from PE analysis)
1-Year Target
$17.61
(+6%)
2-Year Target
$18.61
(+12%)
3-Year Target
$19.67
(+18%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$16.71
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 13.8%)
$36.05
(+116%)
Base:
(SPY PE: 14.8, Growth: 13.8%)
$24.55
(+47%)
Bear:
(PE: 12.6, Growth: 13.8%)
$20.86
(+25%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 43.54 | Current EPS (TTM): $0.37
Bull Case
$35.44
(+113%)
Analyst growth 100.0%, PE expands to 47.9
Base Case
$32.22
(+93%)
Market implied 100.0%, PE stable at 43.5
Bear Case
$10.95
(-34%)
Severe decline -20.0%, PE contracts to 37.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 9:34 PM ET
Data refreshes hourly during market hours. Next update: 10:34 PM
Data refreshes hourly during market hours. Next update: 10:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
